Albert Einstein is credited with defining insanity as doing the same thing over and over again and expecting different results. It was not irrational to test the hypothesis that lowering glucose prevents heart disease, but careful studies have done just that over and over again. The data indicate that glucose is a powerful biomarker but not the major mechanistic mediator of atherosclerosis in diabetes. Developing new approaches to diabetic cardiovascular disease will require pursuing glucose-independent mechanisms at the bench encompassing the broad spectrum of abnormalities that plague patients with the most common metabolic disorder in the world.
sclerosis could be modulated in mice and cell culture to determine effects on insulin signaling, cytokine production, inflammation and vascular disease. Attractive p53 targets include TP53-induced glycolysis and apoptosis regulator 11 , which regulates glycolysis and reactive oxygen species, and the sestrins 12 , which affect genotoxic stress and suppress mTOR (a nutritional sensor known to be affected by diabetes).
Starvation also activates autophagy 13 , which is an adaptive response to nutritional deficiency, a mechanism for eliminating damaged organelles, and a process regulated by the mTOR pathway. Autophagy is promoted by unesterified cholesterol (a component of the atherosclerotic plaque), CD40 ligand (present in atherosclerotic lesions and known to induce proatherogenic chemokines), signaling by Tolllike receptor 4 (a mediator of innate immunity as well as insulin resistance), and damage-regulated autophagy modulator (a p53-inducible protein that provides a nexus for interfacing with genotoxic stress pathways).
One might predict that relative starvation of the vasculature in diabetes would accelerate autophagy and disrupt normal function. Consistent with this idea, interference with autophagy seems to prevent myocardial ischemia-reperfusion injury 14 . However, the loss of beta cell-specific autophagy results in metabolic dysfunction in mice 15 , suggesting that extremes of autophagy modulation are maladaptive.
Altering the expression of key autophagy genes such as Becn1 (encoding beclin-1, or Atg6) within a physiologically relevant range in mouse models of atherosclerosis could provide proof of principle that the response to cellular starvation in diabetes affects macrovascular disease.
insulin resistance, the insulin receptor does not appropriately initiate the kinase cascade that results in nutrient acquisition, and cells are relatively starved (Fig. 1) .
Relative starvation leads to genomic stress. Nutrient deprivation decreases energy stores. This alters metabolism, in part through the induction of AMP kinase, to increase glycolysis, suppress the pentose phosphate shunt (which produces reducing compounds for fatty acid synthesis as well as neutralization of reactive oxygen species), arrest fatty acid synthesis (through effects on acetyl-CoA carboxylase) and accelerate fatty acid oxidation.
Collectively, these responses increase oxidative stress promoting genomic stress and DNA damage. Recently, a genetic variant previously linked with coronary risk was found to be associated with macrovascular events in people with diabetes 9 . Known genes at this locus encode cylcin-dependent kinase-4 inhibits a and b (INK4a, INK4b) and alternate reading frame (ARF), which suppress genomic instability and tumor formation. DNA damage is implicated in cancer syndromes, but atherosclerosis and insulin resistance also characterize individuals with DNA repair disorders such as Werner's syndrome, Hutchison-Gilford progeria, Cockayne's syndrome and ataxia-telangiectasia (caused by mutations in the ATM gene encoding ataxia telangiectasia mutated protein). Decreased amounts of the tumor suppressor p53 increase atherosclerosis, increased amounts of p53 and ARF diminish oxidative stress-mediated phenotypes, and pharmacologic activation of the ATM-p53 pathway has insulin-sensitizing as well as antiatherogenic effects 10 .
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Fanning the flames of obesity-induced inflammation
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Recent back-to-back studies show that obesity perturbs inflammatory gene networks and hint at causal relationships between inflammation and disease traits associated with the metabolic syndrome 1,2 . Approaches used in these studies are distinct from classical genome-wide associational studies or tissue-specific mRNA expression profiling, as they rely on neural networks and high-powered computational methods to interconnect genetic, genomic and environmental data into a causal model.
Gene expression was assessed as a quantitative trait to predict which features of obesity promote disease. The first study revealed a tendency toward activation of an inflammation network in adipose tissue of Icelandic subjects with a high body mass index 1 . Parallel results were found in the second study, which similarly analyzed adipose tissue and liver from obese and control mice 2 . A major strength of this approach is that specific perturbations can be considered in the context of other changes occurring not only in the tissue being examined, but also simultaneously in other tissues and in the context of genetics, environmental determinants and even time. As a The complex processes linking obesity to its deleterious health consequences are finally being unraveled. Inflammation is receiving increased attention for its potential role in the pathogenesis of disorders ranging from insulin resistance and type 2 diabetes to fatty liver and cardiovascular disease.
biology, and findings are limited by the quantity and accuracy of the data used to construct the networks.
The relatively unbiased approach used in these studies affirms a role for inflammation in the pathogenesis of metabolic diseases. The approach should also provide new biomarkers for obesity and related metabolic diseases. An additional major promise of such systems biology approaches is in their application to drug discovery. The administration of a drug provides a single perturbation that should influence multiple components of the system. The approach should provide valuable information about mechanisms of action, not only for the drug's beneficial effects but also for side effects that may limit utility. Identification of new biomarkers for assessing response to a drug should also provide avenues for personalized medicine by tailoring interventions to an individual's underlying disease mechanisms.
How do these new findings fit the larger, emerging picture of obesity-induced inflammation? Epidemiological evidence relating inflammation to type 2 diabetes and obesity has existed since the 1950s 3 but was not considered in terms of pathogenesis until the 1990s. The list of markers shown to be elevated in obesity includes white blood cell count and plasma concentrations of sialic acid, C-reactive protein, tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), among other factors 3, 4 , and the list continues to grow.
TNF-α was hypothesized to mediate obesityinduced inflammation, because it is produced in adipose tissue and TNF-α neutralization in mice curbed insulin resistance 5 . However, TNF-α neutralization trials in humans were negative 6 , which dampened enthusiasm not only for TNF-α as a drug target in type 2 diabetes but also for the 'inflammation hypothesis' of type 2 diabetes. New discoveries continued to rekindle interest in this area of investigation despite these ongoing debates.
The discovery that obesity also activates intracellular pathways, including the IKK-β-NF-κB and JNK pathways 7, 8 , added fuel to the inflammatory hypothesis. Upregulation of the IKK-β-NF-κB axis leads to excess production of multiple potential mediators of inflammation, whereas JNK activation impinges upon insulin signaling through phosphorylation of serine residues of insulin receptor substrate-1.
Stimuli potentially activating both IKK-β-NF-κB and JNK in obesity can be separated into extracellular ligands, such as the proinflammatory cytokines TNF-α, IL-1β and IL-6 or fatty acids binding to Toll-like receptors, and intracellular stimuli such as endoplasmic reticulum or oxidative stress, and ceramides 3 . Determining which processes initiate obesityinduced inflammation is an active area of investigation.
The discovery of macrophages in obese adipose tissue was another milestone toward better understanding obesity-induced inflammation 9, 10 . Macrophages seem to accumulate in obese fat in response to adipocyte stress and death, possibly owing to insufficient angiogenesis and hypoxia. Although the role of the macrophages is incompletely understood, they may participate in the development insulin resistance, type 2 diabetes and cardiovascular disease through production of proinflammatory cytokines, chemokines, and other factors. Inhibition of NF-κB or JNK in macrophages improves insulin resistance 11, 12 .
Importantly for people with type 2 diabetes or cardiovascular disease, these recent discoveries promise potential new avenues for treatment. Despite earlier failures with TNF-α blockers, it now seems that inflammation will provide viable therapeutic targets. Two approaches are already being validated in clinical trials: anti-inflammatory salicylates and IL-1 blockade. The salicylates are atypical members of the nonsteroidal anti-inflammatory class of drugs, which target NF-κB as opposed to the cyclooxygenase enzymes Cox1 and Cox2. Salsalate, a salicylate prodrug, has been shown to have glucose-lowering efficacy in small trials 13 , with larger Targeting Inflammation using Salsalate for Type 2 Diabetes (TINSAL-T2D) trials ongoing. The recombinant IL-1 receptor antagonist anakinra, currently approved for use in rheumatoid arthritis, also improves glycemia in individuals with type 2 diabetes 14 . IL-1 blockade and salsalate are both likely to improve beta cell function and insulin resistance, although anakinra reportedly targets beta cells, and salsalate effects have focused on insulin sensitivity 13, 14 .
Although it is too early to say whether salicylate or anakinra will go the distance, these approaches have already validated inflammation as a pharmacological target in type 2 diabetes. Moreover, these approaches are vastly different from one another, as anakinra is an injected biological that binds extracellular IL-1 proteins, whereas salsalate is an orally delivered small molecule whose active product, salicylate, inhibits intracellular transcription. This suggests that numerous nodes or points within inflammation networks may be targeted in diabetes-which is good news, as the therapeutic area of inflammation is rich in molecular targets that have already received great attention from the pharmaceutical industry.
Of course, salsalate and anakinra target inflammation systemically, whereas the potential targets identified by the back-to-back studies of Schadt and Stefansson and their colleagues are restricted to adipose tissue 1, 2 . Unless the studies are expanded to other tissues, which is both feasible and a strength of the approach, the potential targets they identify will be in adipose tissue. Modulation of these targets could have systemic effects and even beta cell effects, but this needs to be shown. The authors 1,2 point out that several genes already known to be related to obesity, Zfp90, C3ar1, Hsd11b1 and Tgfbr2, were identified by their approach and thus validated it. The independent ablation of three additional genes-Lpl, Lactb and Ppm1l-led to an overweight or obese phenotype 2 .
Additional studies will determine whether these are bona fide drug targets or 'just' research tools. But it is certain that these types of systems biology, network analysis approaches will prove to be invaluable in the hunt for safer and more efficacious drugs that are tailored to obese individuals and patients with diabetes.
